Operating Segments (Tables)

6 Months Ended

Jun. 30, 2018

Operating Segments [Abstract]

Summary of operating segments

	Three Months Ended June 30,
	2018			2017
Revenues
Vaccines/BioDefense	$	1,449,044		$	990,971
BioTherapeutics		276,501			-
Total	$	1,725,545		$	990,971
Income (Loss) from Operations
Vaccines/BioDefense	$	30,299		$	197,270
BioTherapeutics		(923,960	)		(1,574,261	)
Corporate		(695,629	)		(939,838	)
Total	$	(1,589,290	)	$	(2,316,829	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	4,512		$	9,611
BioTherapeutics		5,345			8,077
Corporate		1,313			933
Total	$	11,170		$	18,621
Interest Income, Net
Corporate	$	32,948		$	5,231
Share-Based Compensation
Vaccines/BioDefense	$	12,818		$	14,973
BioTherapeutics		21,898			22,827
Corporate		55,709			56,247
Total	$	90,425		$	94,047

	Six Months Ended June 30,
	2018			2017
Revenues
Vaccines/BioDefense	$	2,258,300		$	2,321,855
BioTherapeutics		587,018			-
Total	$	2,845,318		$	2,321,855
Income (Loss) from Operations
Vaccines/BioDefense	$	(55,906	)	$	333,870
BioTherapeutics		(2,445,308	)		(2,601,816	)
Corporate		(1,482,177	)		(1,787,073	)
Total	$	(3,983,391	)	$	(4,055,019	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	8,992		$	19,380
BioTherapeutics		10,729			17,644
Corporate		2,663			2,647
Total	$	22,384		$	39,671
Interest Income, Net
Corporate	$	49,843		$	9,984
Share-Based Compensation
Vaccines/BioDefense	$	28,486		$	32,971
BioTherapeutics		50,216			72,597
Corporate		119,693			135,106
Total	$	198,395		$	240,674

	As of  June 30, 2018		As of December 31, 2017
Identifiable Assets
Vaccines/BioDefense	$	1,443,142	$	906,416
BioTherapeutics		166,364		116,344
Corporate		4,542,632		8,526,891
Total	$	6,152,139	$	9,549,651